Advancing Vaccine Technology: GeoVax Labs' Breakthrough in Cross-Variant Protection
Update: 2025-12-18
Description
GeoVax Labs, Inc. showcases the effectiveness of their GEO-CM04S1 vaccine against the Omicron variant, emphasizing the role of T-cell immunity. The study highlights the importance of T-cell responses in next-generation COVID-19 vaccines, demonstrating broader and more durable immunity compared to spike-only vaccines. This breakthrough paves the way for enhanced protection, especially for immunocompromised individuals, with ongoing Phase 2 trials for GEO-CM04S1.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
